# Understanding the Failure of Medical Therapy in PFO-Associated Stroke and the Benefits of Closure: A Narrative Review

## TL;DR

This review explains why medical therapy fails in some PFO-related strokes and why PFO closure may be more effective in preventing recurrence.

## Contribution

The paper synthesizes recent evidence on PFO stroke mechanisms and evaluates how anatomical features influence therapy outcomes.

## Key findings

- PFO closure reduces stroke recurrence more than medical therapy in high-risk patients.
- Anticoagulation may fail due to unaddressed mechanisms like paradoxical embolism.
- High-risk PFO features and scoring systems help identify patients likely to benefit from closure.

## Abstract

Patent foramen ovale (PFO) is present in roughly one quarter of adults and is over-represented among younger patients with cryptogenic ischemic stroke. The past decade has produced compelling evidence from randomized trials showing that PFO closure is beneficial than medical therapy in preventing recurrent ischemic stroke in appropriately selected patients. Despite this, anticoagulation continues to be used when closure is not feasible, declined, contraindicated, or considered after recurrent events. The observation that some patients experience “breakthrough” stroke or transient ischemic attack (TIA) despite therapeutic anticoagulation raises a critical question: why does medical therapy fail in PFO-associated stroke, and why does closure appear superior? This narrative review synthesizes the latest evidence on the pathophysiology of PFO-associated stroke, with attention to mechanisms that remain incompletely addressed by anticoagulation. It analyzes randomized trial data comparing antiplatelet therapy, anticoagulation, and transcatheter closure. It examines the role of high-risk PFO anatomical characteristics, the Risk of Paradoxical Embolism (RoPE) score, and the PFO-Associated Stroke Causal Likelihood (PASCAL) classification in understanding medical therapy failure. Additionally, the review explores whether PFO “type” predicts anticoagulation failure and highlights future research directions needed to further optimize therapy. In conclusion, in appropriately selected patients with high-risk PFO features, closure provides greater stroke risk reduction than medical therapy alone, albeit with small absolute risk differences and a procedural risk of atrial fibrillation.